Trademark: AKOUOS 2178794
Word
AKOUOS
ID
2178794
Trademark Type
Word
Status
Registered: Registered/protected
Application Date
13 May 2021
Registration Date
13 May 2021
Renewal Date
13 May 2031
Owner(s)
Service
McCullough Robertson Lawyers
Goods and Services:
Class 5:
Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; biologics and small molecules in the nature of pharmaceutical preparations for use in treating diseases and conditions involving the ear in the nature of genetic conditions causing hearing loss; gene therapy products to restore, improve, and preserve hearing; gene therapy products to treat inner ear disorders and conditions; viral vectors, non-viral vectors, gene therapy vectors all for medical purposes in gene therapy for inner ear disorders and conditions; biotechnological platform technology, namely, biological nanoparticles and adenoviruses for gene delivery to biological cells that includes adeno-associated viral (AAV) vectors to provide a platform for specific expression of biologics with therapeutic effect in gene therapy to restore, improve and preserve hearing; biotechnological platform technology, namely, biological nanoparticles and adenoviruses for gene delivery to biological cells that includes adeno-associated viral (AAV) vectors to provide a platform for specific expression of biologics with therapeutic effect in gene therapy to treat inner ear disorders and conditions
Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; biologics and small molecules in the nature of pharmaceutical preparations for use in treating diseases and conditions involving the ear in the nature of genetic conditions causing hearing loss; gene therapy products to restore, improve, and preserve hearing; gene therapy products to treat inner ear disorders and conditions; viral vectors, non-viral vectors, gene therapy vectors all for medical purposes in gene therapy for inner ear disorders and conditions; biotechnological platform technology, namely, biological nanoparticles and adenoviruses for gene delivery to biological cells that includes adeno-associated viral (AAV) vectors to provide a platform for specific expression of biologics with therapeutic effect in gene therapy to restore, improve and preserve hearing; biotechnological platform technology, namely, biological nanoparticles and adenoviruses for gene delivery to biological cells that includes adeno-associated viral (AAV) vectors to provide a platform for specific expression of biologics with therapeutic effect in gene therapy to treat inner ear disorders and conditions
Class 10:
Drug delivery systems; viral vector delivery platforms for gene therapy; medical devices for use in treating diseases and conditions involving the ear in the nature of genetic conditions causing hearing loss
Drug delivery systems; viral vector delivery platforms for gene therapy; medical devices for use in treating diseases and conditions involving the ear in the nature of genetic conditions causing hearing loss
Class 41:
Providing education information regarding inner ear disorders and conditions, hearing loss and genetics via a website
Providing education information regarding inner ear disorders and conditions, hearing loss and genetics via a website
Class 42:
Scientific research consulting in the field of inner ear disorders and conditions and hearing loss; custom development of biochemical reagents and biological nanoparticles, namely, therapeutic compositions that include adeno-associated viral (AAV) vectors to provide a platform for specific expression of biologics with therapeutic effect in gene therapy to restore, improve and preserve hearing; custom development of biochemical reagents and biological nanoparticles, namely, therapeutic compositions that include adeno-associated viral (AAV) vectors to provide a platform for specific expression of biologics with therapeutic effect in gene therapy to treat inner ear disorders and conditions
Scientific research consulting in the field of inner ear disorders and conditions and hearing loss; custom development of biochemical reagents and biological nanoparticles, namely, therapeutic compositions that include adeno-associated viral (AAV) vectors to provide a platform for specific expression of biologics with therapeutic effect in gene therapy to restore, improve and preserve hearing; custom development of biochemical reagents and biological nanoparticles, namely, therapeutic compositions that include adeno-associated viral (AAV) vectors to provide a platform for specific expression of biologics with therapeutic effect in gene therapy to treat inner ear disorders and conditions